Targeting Engineered Nanoparticles for Breast Cancer Therapy
Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of the...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/956046552f0446d194d44db625b95a11 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:956046552f0446d194d44db625b95a11 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:956046552f0446d194d44db625b95a112021-11-25T18:40:58ZTargeting Engineered Nanoparticles for Breast Cancer Therapy10.3390/pharmaceutics131118291999-4923https://doaj.org/article/956046552f0446d194d44db625b95a112021-11-01T00:00:00Zhttps://www.mdpi.com/1999-4923/13/11/1829https://doaj.org/toc/1999-4923Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC.Kumar GanesanYan WangFei GaoQingqing LiuChen ZhangPeng LiJinming ZhangJianping ChenMDPI AGarticlenanoparticlesligandsengineeringtherapeutic effectsbreast cancerPharmacy and materia medicaRS1-441ENPharmaceutics, Vol 13, Iss 1829, p 1829 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
nanoparticles ligands engineering therapeutic effects breast cancer Pharmacy and materia medica RS1-441 |
| spellingShingle |
nanoparticles ligands engineering therapeutic effects breast cancer Pharmacy and materia medica RS1-441 Kumar Ganesan Yan Wang Fei Gao Qingqing Liu Chen Zhang Peng Li Jinming Zhang Jianping Chen Targeting Engineered Nanoparticles for Breast Cancer Therapy |
| description |
Breast cancer (BC) is the second most common cancer in women globally after lung cancer. Presently, the most important approach for BC treatment consists of surgery, followed by radiotherapy and chemotherapy. The latter therapeutic methods are often unsuccessful in the treatment of BC because of their various side effects and the damage incurred to healthy tissues and organs. Currently, numerous nanoparticles (NPs) have been identified and synthesized to selectively target BC cells without causing any impairments to the adjacent normal tissues or organs. Based on an exploratory study, this comprehensive review aims to provide information on engineered NPs and their payloads as promising tools in the treatment of BC. Therapeutic drugs or natural bioactive compounds generally incorporate engineered NPs of ideal sizes and shapes to enhance their solubility, circulatory half-life, and biodistribution, while reducing their side effects and immunogenicity. Furthermore, ligands such as peptides, antibodies, and nucleic acids on the surface of NPs precisely target BC cells. Studies on the synthesis of engineered NPs and their impact on BC were obtained from PubMed, Science Direct, and Google Scholar. This review provides insights on the importance of engineered NPs and their methodology for validation as a next-generation platform with preventive and therapeutic effects against BC. |
| format |
article |
| author |
Kumar Ganesan Yan Wang Fei Gao Qingqing Liu Chen Zhang Peng Li Jinming Zhang Jianping Chen |
| author_facet |
Kumar Ganesan Yan Wang Fei Gao Qingqing Liu Chen Zhang Peng Li Jinming Zhang Jianping Chen |
| author_sort |
Kumar Ganesan |
| title |
Targeting Engineered Nanoparticles for Breast Cancer Therapy |
| title_short |
Targeting Engineered Nanoparticles for Breast Cancer Therapy |
| title_full |
Targeting Engineered Nanoparticles for Breast Cancer Therapy |
| title_fullStr |
Targeting Engineered Nanoparticles for Breast Cancer Therapy |
| title_full_unstemmed |
Targeting Engineered Nanoparticles for Breast Cancer Therapy |
| title_sort |
targeting engineered nanoparticles for breast cancer therapy |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/956046552f0446d194d44db625b95a11 |
| work_keys_str_mv |
AT kumarganesan targetingengineerednanoparticlesforbreastcancertherapy AT yanwang targetingengineerednanoparticlesforbreastcancertherapy AT feigao targetingengineerednanoparticlesforbreastcancertherapy AT qingqingliu targetingengineerednanoparticlesforbreastcancertherapy AT chenzhang targetingengineerednanoparticlesforbreastcancertherapy AT pengli targetingengineerednanoparticlesforbreastcancertherapy AT jinmingzhang targetingengineerednanoparticlesforbreastcancertherapy AT jianpingchen targetingengineerednanoparticlesforbreastcancertherapy |
| _version_ |
1718410849455964160 |